Improves Daytime Energy LevelsNCT07893561
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
A study testing Adrenal Adapt in people with Improves Daytime Energy Levels and Reduces Afternoon Energy Crashes and Midday Fatigue, run by Bioligent at 1 site in United States.
Trial summary
This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive performance over a 12-week intervention period in 40 healthy adults aged 18-60. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue, Improves Overall Sleep Quality and Restorative Sleep
- What is being tested?
- Adrenal Adapt
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Sep 2026to 2 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18-60 years at the time of enrollment.
- Experiencing difficulty with at least two of the following: sleep quality (including difficulty falling asleep, nighttime awakenings, or unrefreshing sleep), daytime fatigue or low energy, and/or subjective feelings of elevated stress.
- Generally healthy - does not live with any uncontrolled chronic disease that would interfere with study participation or confound study outcomes.
- If currently taking medications, supplements, or herbal remedies targeting sleep, stress, or energy, willing to maintain that routine unchanged for the study duration without introducing any other new products.
- Willing to take 1 capsule of Adrenal Adapt three times daily with a meal (morning, afternoon, evening) for 12 weeks, not exceeding 3 capsules per day.
- Willing to avoid excessive caffeine and alcohol for the duration of the study, defined as more than 400mg of caffeine per day, more than 15 alcoholic drinks per week for men and more than 7 alcoholic drinks per week for women.
Show all 9Show fewer
- Willing to maintain their current diet, sleep habits, and activity levels for the duration of the trial.
- Resides in the United States with a valid shipping address.
- Has consistent access to a smartphone or computer and a reliable internet connection sufficient to complete digital surveys.
Who cannot join
- Currently pregnant, breastfeeding, or planning to become pregnant at any point during the study period.
- Currently taking anticoagulant medications (e.g., warfarin, heparin, or direct oral anticoagulants), as specified in the product's known contraindications.
- Known allergy or hypersensitivity to any ingredient in Adrenal Adapt (including Hypromellose capsule shell, white rice flour, stearic acid, silicon dioxide, or any of the botanical extracts).
- Diagnosed with a clinically significant psychiatric disorder (e.g., major depressive disorder or bipolar disorder) that could confound subjective outcome assessments or interfere with study participation.
- Diagnosed with a sleep disorder for which pharmacological treatment has been prescribed (e.g., narcolepsy, sleep apnea treated with a CPAP device and prescription medications, insomnia disorder treated with prescription hypnotics).
- Generated by Citruslabs · 02c23d89-a524-4659-bc54-5792f4592244 Planning to introduce any new prescription medications, supplements, or herbal products targeting sleep, stress, or energy during the study period.
Show all 9Show fewer
- History of substance use disorder or currently using recreational drugs that may affect sleep or stress physiology.
- Planning surgery or a major medical procedure during the 12- week study period.
- Currently enrolled in or planning to enroll in another research study during the study period.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Citruslabs
Las Vegas, Nevada, 89118
About this study
This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive performance over a 12-week intervention period in 40 healthy adults aged 18-60.
- Conditions
- Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue, Improves Overall Sleep Quality and Restorative Sleep, Helps People Fall Asleep Faster and Wake Less During the Night, Helps People Wake Feeling Refreshed, Improves the Body's Resilience and Recovery in Response to Everyday Stress
- Being tested
- Adrenal Adapt
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Adrenal AdaptDietary supplement
All enrolled participants take 1 capsule of Adrenal Adapt three times daily (once in the morning with the first meal of the day, once in the afternoon with the midday meal, and once in the evening with the evening meal), not to exceed 3 capsules per day, for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Adrenal Adapt Arm | Experimental | Not described Receives: Dietary Supplement: Adrenal Adapt |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Overall Sleep Quality
Change from Baseline in self-reported overall sleep quality (restorative sleep), as assessed by validated sleep quality questionnaire items
Measured: Baseline to Week 12
Change in Sleep Onset Latency
Change from Baseline in self-reported speed of falling asleep, as assessed by validated sleep quality questionnaire items
Measured: Baseline to Week 12
Change in Nighttime Awakenings
Change from Baseline in self-reported frequency of nighttime awakenings (sleep maintenance), as assessed by validated sleep quality questionnaire items
Measured: Baseline to Week 12
Change in Subjective Morning Refreshment
Change from Baseline in self-reported subjective sense of waking refreshed, as assessed by validated sleep quality questionnaire items
Measured: Baseline to Week 12
Secondary outcomes (1)
Change in Overall Daytime Energy Levels
Change from Baseline in self-reported overall daytime energy levels, as assessed by self-reported energy and fatigue questionnaire items
Measured: Baseline to Weeks 4, 8, and 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start9 Sep 2026
- Primary completion2 Dec 2026 (estimated)
- Study completion2 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Improves Daytime Energy LevelsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bioligent
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07893561
- Sponsor's protocol ID
- BIOLI-10180
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
- ClinicalTrials.gov ID
- NCT07893561
- Acronym / sponsor ID
- BIOLI-10180
- Conditions
- Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue, Improves Overall Sleep Quality and Restorative Sleep, Helps People Fall Asleep Faster and Wake Less During the Night, Helps People Wake Feeling Refreshed, Improves the Body's Resilience and Recovery in Response to Everyday Stress
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- BioligentIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 9 Sep 2026 (actual)
- Primary completion
- 2 Dec 2026 (estimated)
- Study completion
- 2 Dec 2026 (estimated)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive performance over a 12-week intervention period in 40 healthy adults aged 18-60.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adrenal Adapt Arm | Experimental | Dietary Supplement: Adrenal Adapt |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Adults aged 18-60 years at the time of enrollment.
- Experiencing difficulty with at least two of the following: sleep quality (including difficulty falling asleep, nighttime awakenings, or unrefreshing sleep), daytime fatigue or low energy, and/or subjective feelings of elevated stress.
- Generally healthy - does not live with any uncontrolled chronic disease that would interfere with study participation or confound study outcomes.
- If currently taking medications, supplements, or herbal remedies targeting sleep, stress, or energy, willing to maintain that routine unchanged for the study duration without introducing any other new products.
- Willing to take 1 capsule of Adrenal Adapt three times daily with a meal (morning, afternoon, evening) for 12 weeks, not exceeding 3 capsules per day.
Key exclusion criteria (9 listed)
- Currently pregnant, breastfeeding, or planning to become pregnant at any point during the study period.
- Currently taking anticoagulant medications (e.g., warfarin, heparin, or direct oral anticoagulants), as specified in the product's known contraindications.
- Known allergy or hypersensitivity to any ingredient in Adrenal Adapt (including Hypromellose capsule shell, white rice flour, stearic acid, silicon dioxide, or any of the botanical extracts).
- Diagnosed with a clinically significant psychiatric disorder (e.g., major depressive disorder or bipolar disorder) that could confound subjective outcome assessments or interfere with study participation.
- Diagnosed with a sleep disorder for which pharmacological treatment has been prescribed (e.g., narcolepsy, sleep apnea treated with a CPAP device and prescription medications, insomnia disorder treated with prescription hypnotics).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adrenal AdaptAll enrolled participants take 1 capsule of Adrenal Adapt three times daily (once in the morning with the first meal of the day, once in the afternoon with the midday meal, and once in the evening with the evening meal), not to exceed 3 capsules per day, for 12 weeks. | Dietary supplement | Adrenal Adapt Arm |
Primary outcome
Change in Overall Sleep Quality
Time frame: Baseline to Week 12
Change from Baseline in self-reported overall sleep quality (restorative sleep), as assessed by validated sleep quality questionnaire items
Change in Sleep Onset Latency
Time frame: Baseline to Week 12
Change from Baseline in self-reported speed of falling asleep, as assessed by validated sleep quality questionnaire items
Change in Nighttime Awakenings
Time frame: Baseline to Week 12
Change from Baseline in self-reported frequency of nighttime awakenings (sleep maintenance), as assessed by validated sleep quality questionnaire items
Change in Subjective Morning Refreshment
Time frame: Baseline to Week 12
Change from Baseline in self-reported subjective sense of waking refreshed, as assessed by validated sleep quality questionnaire items
1 secondary outcome
Change in Overall Daytime Energy Levels
Time frame: Baseline to Weeks 4, 8, and 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Adrenal Adapt in people with Improves Daytime Energy Levels and Reduces Afternoon Energy Crashes and Midday Fatigue, run by Bioligent at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patrick Renner (42424250284, hello@citruslabs.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Overall Sleep Quality (time frame: Baseline to Week 12). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.